Navigation Links
Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
Date:4/22/2009

e same target, but can bind both targets simultaneously. Results showed the CD79BxDR SCORPION molecule elicited strong Antibody-Dependent Cellular Cytotoxicity (ADCC) as well as highly potent direct killing, confirming the ability of Trubion's SCORPION molecules to retain key effector functions that are known to be related to efficacy of monoclonal antibodies. In addition, the data also demonstrated in assays against the NHL-derived DoHH2 cell line, that Trubion's SCORPION multispecific therapeutic was 100 times more potent than both rituximab and the combination of the individual mono-specific SMIP molecules against the respective CD79B and HLA-DR targets. This enhanced potency was shown to be restricted to the depletion of B-cells when in the presence of T cells, as 48 hour incubation with primary human peripheral blood mononuclear cells showed selective depletion of B (CD19+) but not T (CD3+) cells.

A copy of this poster presentation is available on Trubion's website at http://investors.trubion.com/events.cfm.

Trubion's SCORPION(TM) Therapeutics

Like Trubion's SMIP(TM) therapeutics -- single-chain polypeptides comprising one binding domain, one hinge domain and one effector domain -- SCORPION therapeutics are also novel, single-chain polypeptides comprised of functional domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion's SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor interactions or that manipulate cellular signaling pathways by cross-linking multiple cell surface receptors. SCORPION therapeutics have long in vivo half-lives, can have other intact effector f
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
3. Trubion Announces Presentations at Upcoming Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
10. Trubion Announces Presentations at April/May Investor Conferences
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ON , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. ... orders totalling $5.7 million. The orders are for air emission abatement ... "Of particular note is a large order for a municipality ... equipment will be replacing a competitor,s system that failed to ... in our engineered solutions," said Derek S. Webb , ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Mexico Biomedical Sensors Market - Growth, Trends ... The Mexico Biomedical Sensors market is ... of 2.68% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... TORONTO , Aug. 31, 2015 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... be advancing its lead candidate, PPL-003, to an Investigational ... dry eye disease and uveitis.  PPL recently completed a ... where topical PPL-003 solution achieved highly significant efficacy and ...
(Date:8/31/2015)... Calif. , Aug. 31, 2015 FLX ... and development of novel cancer immunotherapies, announced today that ... as Chief Executive Officer and William Ho , ... Ho join an experienced management team led by veterans ... Fridman , Ph.D., Chief Scientific Officer; Jay Powers ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4
... NEW YORK, April 18, 2011 KellBenx, a biotechnology ... (NIPD) of genetic and inherited disorders, announced today that ... Medical Center to research a new blood test that ... pregnancy – or even before women become pregnant. Preterm ...
... no larger than viruseshave been constructed through a revolutionary ... Liu and their colleagues at Arizona State University,s Biodesign ... construct arbitrary, two and three-dimensional shapes, mimicking those commonly ... ultimately find their way into a wide array of ...
... Carmell Therapeutics, a company that manufactures novel blood plasma-based ... closed on a Series A financing it will use ... for early clinical validation for the Company,s first products. ... Light Capital Partners, a private investment firm that invests ...
Cached Biology Technology:KellBenx Secures Worldwide Agreement With Cedars-Sinai Medical Center for Biomarker Technology to Predict Premature Births 2New DNA nanoforms take shape 2New DNA nanoforms take shape 3New DNA nanoforms take shape 4Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/10/2015)... The latest 364 page report from ... the global border security market . Visiongain ... 2015. Now: Border security is hard to achieve ... business critical issue you need to know about - and ... analysis of how this will impact your company and the ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... patient society representatives gathered in Valencia, Spain for the ... Osteoporosis Patient Societies. Osteoporosis is a widespread ... as many as one in two women and one ... International Osteoporosis Foundation (IOF) CEO Patrice McKenney stated, ...
... has awarded one of this year,s ERC Advanced Grants ... well-established research in the field of biosilicates with prize ... is professor at Mainz University,s Institute of Physiological Chemistry. ... and production of genetically engineered enzymes (silicateins) that allow ...
... March 17, 2011 (BRONX, NY) Researchers at ... discovered that members of an enzyme family found in humans ... role in regulating cell motility. Their findings suggest an entirely ... metastatic cancer. , David Sharp, Ph.D. , associate professor ...
Cached Biology News:Enzyme can steer cells or possibly stop them in their tracks 2
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... for 15-20 enhancements when used as directed, ... System is designed to amplify the desired signal detected ... evaluating proteins with low expression., Membrane ... blocking the membrane; 1x solution; 250 ml, ...
... Prior to siRNA library screening, ... be identified and verified for ... Silencer CellReady siRNA Transfection Optimization ... for optimizing transfection conditions in ...
... The MX80 Series of positioning slides ... motor, ballscrew, leadscrew, micrometer, and manual. ... high performance, cost-effective multi-axis systems. These ... bearings, encoder resolutions down to 10 ...
Biology Products: